The FDA’s call comes within a wider push from the US government to alter vaccine policy.
Unlike the US, Mexico is bolstering its mRNA offerings with the help of Moderna’s portfolio.
The approvals stem from the Phase III KEYNOTE-B96 trial data, which was presented at the 2025 ESMO Congress.
Uniphar will act as the exclusive distributor for Lymphir in designated European territories.
Analysts said that Yeztugo’s forecast, which would represent 433% year-over-year growth, is achievable.
THX Pharma is set to receive total payments up to $206.1m.
